ACTRIMS 2023: Evobrutinib safely keeps relapse rates low after 4 years
Evobrutinib, an experimental BTK inhibitor being developed for people with relapsing forms of multiple sclerosis (MS), continues to…
Articles by Inês Martins, PhD
PoNS Device Under Review by FDA for Treating Walking Problems in MS
Helius Medical Technologies has filed an application with the U.S. Food and…
New Patent Filing for QuadraMune Relates to Potential in Aiding Memory
Therapeutics Solutions International has announced filing a new patent covering the memory protective effects of its natural nutritional supplement QuadraMune,…
MS Patients Show Greater Risk of Infections Before and After Diagnosis, Study Finds
Multiple sclerosis (MS) patients have a greater risk of infections, particularly urinary and kidney infections, around the time of…
UT Doctoral Student Wins NIH Fellowship to Study MS Cognitive Changes
A $41,000 fellowship from the National Institutes of Health (NIH) aims to advance research into how changes in brain…
MS Patients More Likely to Need Work Leaves Than General Public, Study Finds
People with multiple sclerosis (MS) spend a significantly greater number of work days each year on sick leave or…
Roche and PicnicHealth Partner Around Data, Open FlywheelMS Study
To speed research and work on more personalized treatments for serious diseases, Roche and its subsidiary Genentech announced a…
US Court Rules in Favor of Mylan, Generic Version of Tecfidera
Generic formulations of dimethyl fumarate — currently sold as Tecfidera by Biogen — were given a green light to…
Obesity Linked to Faster Optic Nerve Atrophy, Study Finds
Multiple sclerosis (MS) patients who are obese experience faster degeneration in optic nerve tissue than do those of…
Biogen, MS Trust Open ‘ACT Myself’ to Help With Emotional Well-being
A new digital tool aims to help people with multiple sclerosis (MS) deal with the emotional burden of their…
Two-hour Ocrevus Infusion Time Approved for MS Patients in Europe
The European Medicines Agency (EMA) approved a shorter infusion time for Ocrevus (ocrelizumab), an…
Cell Therapy ATA188 Safely Easing Disability in Progressive MS, Trial Reports
Atara Biotherapeutics‘ cell-based therapy ATA188 is safe and well-tolerated in people with progressive forms of…
Air Pollution of Urban Life Raises MS Risk, Study from Italy Suggests
Exposure to air pollutants, particularly to fine particle pollutants (2.5 micrometers or less in diameter), seems to increase a person’s…
Learning Physical Task Seen to Trigger Myelin Repair in MS Mouse Model
Movements that are an act of “learning” motor tasks after lesions appear in the protective myelin sheath of neurons seem to…
MS Patients Have More Aluminum Content in Their Brains Than Those Without Neurodegenerative Conditions, Study Finds
People with multiple sclerosis (MS) and other neurological diseases have a significantly higher aluminum content in their brains than…
Blocking Monocytes from Nervous System Eases MS Severity, Early Study Finds
Targeting the MOSPD2 protein may prevent immune cells known as monocytes from entering the central nervous system…
EBV Infections Evident in All 901 MS Patients in German Study
Supporting evidence that infection with Epstein-Barr virus (EBV) could be one of the root causes of multiple sclerosis (MS), a…
Ian Duncan Awarded 2020 Dystel Prize for Discoveries in Myelin Repair
Neuroscientist Ian D. Duncan has been awarded the 2020 John Dystel Prize for Multiple Sclerosis Research for work that advanced…
Long-term Gilenya Use Helps Delay Disability in Relapsing MS, 10-year Study Reports
People with relapsing multiple sclerosis (MS) being treated with Gilenya (fingolimod) for eight or more years show smaller…
NurOwn May Curb Damaging Neuroinflammation in MS, Study Finds
NurOwn, believed to have neuroprotective and repairing effects, may also be able to curb the damaging immune responses that contribute to…
CMSC 2020 Meeting Will Be Free and Online May 26-29
To ensure the safety of its participants during the coronavirus pandemic, this year’s Consortium of Multiple Sclerosis Centers…
Obesity Linked to Faster Optic Nerve Atrophy in MS Patients
Multiple sclerosis (MS) patients who are obese experience a faster degeneration in their optic nerve tissue than those…
Rituximab May Prevent MS if Given at Earliest Disease Signs, Mouse Study Suggests
Using rituximab to prevent multiple sclerosis (MS) in people at risk or in patients still without motor symptoms, and…
Monocytes May Be Better, Safer Targets for MS Therapies, Study Suggests
A subset of monocytes (a type of immune cells) that can infiltrate the central nervous system and drive nerve…
VTS-Aspirin Combos to Ease Flush in RRMS Named Orphan Drug by FDA
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to combinations of VTS-Aspirin plus fumarate…
Potential Antibody Treatment for MS, by Immutep, Moving Toward Clinical Trials
With the development of a cell line that produces significant amounts of Immutep‘s treatment candidate, IMP761, the company is…
Genetic Risk for MS Linked to White Matter Changes in Brains of Children
A high genetic risk for multiple sclerosis (MS) is associated with structural alterations in white matter — brain regions…
HLA-DRB1 Gene Variants Seen to Influence Risk, Activity of Pediatric-onset MS
A variant of the HLA-DRB1 gene — called HLA-DRB1*03 — appears to predispose people to developing multiple sclerosis (MS) in childhood, and…
Atara Pauses Enrollment in Part 2 of Immunotherapy Trial in PPMS and SPMS
In response to the COVID-19 pandemic, Atara Biotherapeutics has temporarily paused patient enrollment in the second and randomized part of…
Bile Acid Supplements May Ease Symptoms of Progressive MS
Multiple sclerosis (MS) patients have lower than usual levels of molecules called bile acids circulating in their blood, a…